These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 27094677)
1. Identification of pyrazolopyridazinones as PDEδ inhibitors. Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677 [TBL] [Abstract][Full Text] [Related]
2. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations. Zhong H; Zhang YJ; Shan XB J Biomol Struct Dyn; 2019 Jun; 37(9):2415-2429. PubMed ID: 30052144 [TBL] [Abstract][Full Text] [Related]
3. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764 [TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex. Bello M; Correa-Basurto J; Vargas-Mejía MÁ Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570 [TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361 [TBL] [Abstract][Full Text] [Related]
6. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. Cheng J; Li Y; Wang X; Dong G; Sheng C J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594 [TBL] [Abstract][Full Text] [Related]
8. An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit Kaya P; Schaffner-Reckinger E; Manoharan GB; Vukic V; Kiriazis A; Ledda M; Burgos Renedo M; Pavic K; Gaigneaux A; Glaab E; Abankwa DK J Med Chem; 2024 Jun; 67(11):8569-8584. PubMed ID: 38758695 [TBL] [Abstract][Full Text] [Related]
9. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780 [TBL] [Abstract][Full Text] [Related]
10. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer. Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019 [TBL] [Abstract][Full Text] [Related]
11. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ. Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178 [TBL] [Abstract][Full Text] [Related]
12. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors. Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817 [TBL] [Abstract][Full Text] [Related]
13. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ. Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325 [TBL] [Abstract][Full Text] [Related]
14. Structure-based development of PDEδ inhibitors. Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847 [TBL] [Abstract][Full Text] [Related]
15. PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization. Muratcioglu S; Jang H; Gursoy A; Keskin O; Nussinov R J Phys Chem B; 2017 Jun; 121(24):5917-5927. PubMed ID: 28540724 [TBL] [Abstract][Full Text] [Related]
16. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells. Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177 [TBL] [Abstract][Full Text] [Related]
17. The KRAS-PDEδ interaction is a therapeutic target. Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design. Chen L; Zhuang C; Lu J; Jiang Y; Sheng C J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Leung ELH; Luo LX; Liu ZQ; Wong VKW; Lu LL; Xie Y; Zhang N; Qu YQ; Fan XX; Li Y; Huang M; Xiao DK; Huang J; Zhou YL; He JX; Ding J; Yao XJ; Ward DC; Liu L Cell Death Dis; 2018 Feb; 9(2):216. PubMed ID: 29440631 [TBL] [Abstract][Full Text] [Related]
20. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity. Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]